Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion

  • Technology appraisal guidance
  • TA305
  • Published: 

History

Review proposal consultation

Background information

Macular oedema (central retinal vein occlusion) - aflibercept solution for injection: equality impact assessment - guidance review

Macular oedema (central retinal vein occlusion) - aflibercept solution for injection: final appraisal determination

Macular oedema (central retinal vein occlusion) - aflibercept solution for injection (1st line): equality impact assessment - scoping

Macular oedema (central retinal vein occlusion) - aflibercept solution for injection (1st line): response to consultee and commentator comments on the draft scope and provisional matrix

Macular oedema (central retinal vein occlusion) - aflibercept solution for injection (1st line): final matrix

Macular oedema (central retinal vein occlusion) - aflibercept solution for injection (1st line): final scope

Macular oedema (central retinal vein occlusion) - aflibercept solution for injection: draft scope - (pre referral)

Macular oedema (central retinal vein occlusion) - aflibercept solution for injection: provisional matrix - (pre referral)